The opioid Olinvyk (oliceridine), administered by IV, has been approved for the management of moderate-to-severe acute pain in controlled settings by the U.S. Food and Drug Administration (USFDA).
Olinvyk will be used short term for adults with pain that is severe enough to require an intravenous opioid and who are not getting adequate treatment with alternatives. The drug is approved only for use in hospitals or other controlled settings and is not for at-home use. The maximum recommended daily dose is 27 mg.
Approval was based on phase 3 data from clinical and open-label trials that included a total of 1,535 patients with moderate-to-severe acute pain. Compared with patients randomly assigned to placebo, those who received Olinvyk after bunion or abdominal surgery reported decreased pain.
As with other opioids, common side effects of Olinvyk are nausea, vomiting, dizziness, headache, and constipation. Olinvyk is contraindicated for patients with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, gastrointestinal obstruction, or known hypersensitivity to Olinvyk. The drug label includes a boxed warning on the risks for addiction, abuse, and misuse; life-threatening respiratory depression; and neonatal opioid withdrawal syndrome, as well as the risks of taking the drug simultaneously with benzodiazepines or other central nervous system antidepressants.
Approval was granted to Trevena.